Floatz logo

fx-1006a

Cardiomyopathy

PfizerPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Cardiomyopathy cohort.

Asset / SponsorPhaseRating
CARVEDILOL
Post Graduate Institute of Medical Education and Research, Chandigarh
Phase 4BB
DESFERRIOXAMINE B
Ospedale Microcitemico
Phase 4BB
Deferiprone
Ospedale Microcitemico
Phase 4BB
Empagliflozin
Post Graduate Institute of Medical Education and Research, Chandigarh
Phase 4BB
Semaglutide
Mayo Clinic
Phase 4BB

View all 21 →

Same molecule, other indications

fx-1006a is also rated in:

familial amyloid neuropathyDormant
A
Indicative ·
87 / 100
View asset →
familial amyloid neuropathyDormant
BBB
Indicative ·
78 / 100
View asset →
amyloidosisDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →